Amneal Pharmaceuticals, Inc. — Director's Dealing 2019

Mar 6, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Amneal Pharmaceuticals, Inc. (AMRX)
CIK: 0001723128
Period of Report: 2019-03-01

Reporting Person: Stewart Robert A (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-01	Stock Option	$13.5	A	402212	Acquired	2029-03-01	Class A Common Stock (402212.0)	Direct
2019-03-01	Restricted Stock Units	$	A	197531	Acquired		Class A Common Stock (197531.0)	Direct

Footnotes

F1: The option vests in four equal annual installments beginning on March 1, 2020.

F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3: The restricted stock units vest in four equal annual installments beginning on March 1, 2020.